HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ASTX029

Also Known As:

2-(6-(5-chloro-2-((oxan-4-yl)amino)pyrimidin-4-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl)-N-(1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl)propanamide

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - ASTX029: 2
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - ASTX029: 2

Experts

1.	Berdini, Valerio: 2 articles (10/2021 - 01/2021)
2.	Bevan, Luke: 2 articles (10/2021 - 01/2021)
3.	Courtin, Aurélie: 2 articles (10/2021 - 01/2021)
4.	East, Charlotte: 2 articles (10/2021 - 01/2021)
5.	Heightman, Tom D: 2 articles (10/2021 - 01/2021)
6.	Kucia-Tran, Justyna: 2 articles (10/2021 - 01/2021)
7.	Martins, Vanessa: 2 articles (10/2021 - 01/2021)
8.	Muench, Sandra: 2 articles (10/2021 - 01/2021)
9.	Munck, Joanne M: 2 articles (10/2021 - 01/2021)
10.	Murray, Christopher W: 2 articles (10/2021 - 01/2021)

Related Diseases

1.

Neoplasms (Cancer)

10/01/2021 - "ASTX029 is currently being evaluated in a first in human phase I-II clinical trial in patients with advanced solid tumors (NCT03520075)."
10/01/2021 - "Overall, these findings highlight the therapeutic potential of a dual-mechanism ERK inhibitor such as ASTX029 for the treatment of MAPK-activated cancers, including those which have acquired resistance to inhibitors of upstream components of the MAPK pathway. "
01/01/2021 - "ASTX029 is currently in a phase I-II clinical trial in patients with advanced solid tumors."
10/01/2021 - "This dual mechanism was demonstrated in cell-free systems, as well as cell lines and xenograft tumor tissue, where the phosphorylation of both ERK and its substrate, ribosomal S6 kinase (RSK), were modulated on treatment with ASTX029. "

Related Drugs and Biologics

1.	Ribosomal Protein S6 Kinases (S6 Kinase)